Company Profile

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Employees

Sector

Biotechnology & Medical Research

More about the company

23-07-06	Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	CI
23-07-06	Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	CI
23-06-14	Lysogene CFO Assumes Same Role at Mauna Kea Technologies	MT
23-05-29	Lysogene: placed in liquidation and delisted
23-05-29	Lysogene to Delist from Euronext amid Judicial Liquidation	MT
23-04-29	Lysogene S.A. Announces Postponement of 2022 Financial Results Release	CI
23-04-17	Lysogene: no takeover bid received for biotech company
23-04-17	Lysogene Fails to Secure Takeover Bid Amid Reorganization	MT
23-03-27	Lysogene: deadline for takeover bids extended
23-02-06	Lysogene: interim CFO confirmed
23-02-06	French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	MT
23-02-03	Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	CI
23-01-25	Lysogene: company placed in receivership

23-10-10	Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
23-09-18	Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	AQ
23-04-29	LYSOGENE : Inside Information / News release on accounts, results	PU
22-12-06	LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)	PU
22-11-29	Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis	PU

23-06-14	Mauna Kea Technologies : A suivre aujourd'hui
23-06-13	Mauna Kea Technologies : Côme de La Tour du Pin (ex-Lysogene) nommé Directeur financier
23-05-29	Lysogene : placé en liquidation et retiré de la cote
23-05-16	Lysogène: audience le 23 mai sur une possible liquidation judiciaire
23-05-02	Lysogene : reporte la publication de ses résultats et envisage une liquidation judiciaire

Manager	Title	Age	Since
Karen Pignet-Aiach CEO	Chief Executive Officer	54	2014-05-08
Côme de La Tour du Pin DFI	Director of Finance/CFO	-	2022-10-31
Marie Trad CTO	Chief Tech/Sci/R&D Officer	-	2022-01-31

Director	Title	Age	Since
Karen Pignet-Aiach CHM	Chairman	54	2019-05-21
Peter Lichtlen BRD	Director/Board Member	58	2018-03-31
Carole Deffez BRD	Director/Board Member	-	2019-09-25

LYSOGENE Stock

Stocks

LYS

FR0013233475

Biotechnology & Medical Research

Latest news: LYSOGENE

Press Releases: LYSOGENE

News in other languages: LYSOGENE

Managers and Directors: LYSOGENE

Bio Diagnostics & Testing

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LYSOGENE	-.--%	-.--%	-	-	5.53M
WUXI APPTEC CO., LTD.	-3.10%	-4.19%	+32.67%	+59.47%	63.48B
ARGENX SE	+2.27%	+1.70%	+12.30%	+82.90%	54.55B
LONZA GROUP AG	-0.52%	+1.54%	+11.05%	+103.27%	53.59B
IQVIA HOLDINGS INC.	+2.95%	+0.91%	+27.97%	+57.57%	44.75B
BEONE MEDICINES AG	+2.05%	-3.54%	+17.66%	+99.77%	41.62B
REVOLUTION MEDICINES, INC.	+0.16%	-4.55%	+218.79%	+910.57%	39.91B
CELLTRION, INC.	-0.74%	-4.46%	+11.00%	+44.65%	32.47B
GENMAB A/S	+21.50%	+37.33%	+92.66%	+80.71%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-6.23%	+26.01%	-8.28%	23.36B
Average	+2.83%	-1.19%	+50.01%	+158.96%	42.27B
Weighted average by Cap.	+2.00%	-1.27%	+45.99%	+158.54%